Belatacept: A novel immunosuppressive agent for kidney transplant recipients

Expert Review of Clinical Immunology

Volumn 8, Issue 8, 2012, Pages 719-728

  Charpentier, Bernard ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

belatacept; immunosuppression; kidney transplantation

Indexed keywords

BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; B LYMPHOCYTE; BASAL CELL CARCINOMA; CELL PROLIFERATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DEATH; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFECTION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIVER FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYOMAVIRUS INFECTION; POSTMARKETING SURVEILLANCE; POSTOPERATIVE COMPLICATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SERODIAGNOSIS; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; POSTOPERATIVE COMPLICATIONS; RECEPTOR CROSS-TALK; T-LYMPHOCYTES; TRANSPLANTATION;

EID: 84869772631     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.79     Document Type: Article

References (68)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. Am. J. Transplant. 11(3), 450-462 (2011).
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman Jr. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349(24), 2326-2333 (2003). (Pubitemid 37509740)
3. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am. J. Transplant. 7(3), 518-526 (2007). (Pubitemid 46376465)
4. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62(1), 311-318 (2002). (Pubitemid 34754077)
5. Matas AJ. Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am. J. Transplant. 11(4), 687-692 (2011).
6. Chapman Jr. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am. J. Transplant. 11(4), 693-697 (2011).
7. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90(1), 68-74 (2010).
8. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N. Engl. J. Med. 363(15), 1451-1462 (2010).
9. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116-126 (2002). (Pubitemid 37323235)
10. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J. Immunol. 149(2), 380-388 (1992).
11. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4(6), 535-543 (1996). (Pubitemid 26233307)
12. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005). (Pubitemid 40563179)
13. Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl Acad. Sci. USA 84(23), 8573-8577 (1987).
14. Gross JA, St John T, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J. Immunol. 144(8), 3201-3210 (1990). (Pubitemid 20149501)
15. Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily Y CTLA-4. Nature 328(6127), 267-270 (1987). (Pubitemid 17108278)
16. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3), 561-569 (1991).
17. Greene JL, Leytze GM, Emswiler J et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271(43), 26762-26771 (1996). (Pubitemid 26359085)
18. Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh MH. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: Inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 62(12), 1942-1945 (1996). (Pubitemid 27014568)
19. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381(6581), 434-438 (1996). (Pubitemid 26162734)
20. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57(12), 1701-1706 (1994). (Pubitemid 24206406)
21. Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl Acad. Sci. USA 89(22), 11102-11105 (1992).
22. Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159(11), 5187-5191 (1997). (Pubitemid 127470041)
23. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94(16), 8789-8794 (1997). (Pubitemid 27335118)
24. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443-453 (2005). (Pubitemid 40313335)
25. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007). (Pubitemid 47089023)
26. He S, Zhou Z, Liu Y et al. Do dietary betaine and the antibiotic florfenicol influence the intestinal autochthonous bacterial community in hybrid tilapia (Oreochromis niloticus ♀ × O. aureus ♂)? World J. Microbiol. Biotechnol. 28(3), 785-791 (2012).
27. Latek R, Fleener C, Lamian V et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 87(6), 926-933 (2009).
28. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J. Immunol. 181(4), 2285-2291 (2008).
29. Tang Q, Henriksen KJ, Boden EK et al. Cutting edge: cd28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 171(7), 3348-3352 (2003). (Pubitemid 37254533)
30. Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 8(10), 2086-2096 (2008).
31. Furuzawa-Carballeda J, Lima G, Uribe-Uribe N et al. High levels of aIDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant. Proc. 42(9), 3489-3496 (2010).
32. Chavez H, Beaudreuil S, Abbed K et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl. Immunol. 17(4), 243-248 (2007). (Pubitemid 46687025)
33. Grimbert P, Audard V, Diet C et al. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belataceptmediated co-stimulatory blockade. Nephrol. Dial. Transplant. 26(3), 1087-1093 (2011).
34. Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31(4), 588-595 (2011).
35. Riella LV, Liu T, Yang J et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am. J. Transplant. 12(4), 846-855 (2012).
36. Paul WE. Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77(9), 1859-1870 (1991).
37. Ganguly BJ, Kulbokas EJ, Brickman D et al. A comparison of the peripheral blood mRNA transcriptional profiles of belataceptand cyclosporine-treated renal transplant patients. Transplant. Int. 24(Suppl. S2), Abstract MO-041, 116 (2011).
38. Shen J, Gelb JS, Townsend RM et al. Rationale for belatacept less-intensive (LI) regimen in renal transplant recipients. Transplant. Int. 24(Suppl. s2), Abstract P-103, 255 (2011).
39. Zhou Z, Shen J, Kaul K, Pfister M, Roy A. Belatacept population pharmacokinetics in renal transplant patients. Am. J. Transplant. 10(Suppl. 4), Abstract 1505, 467 (2010).
40. Vincenti F, Larsen C, Durrbach A et al.; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8), 770-781 (2005). (Pubitemid 41215486)
41. Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J. Am. Soc. Nephrol. 21(9), 1587-1596 (2010).
42. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10(3), 535-546 (2010).
43. Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12(1), 210-217 (2012).
44. Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12(3), 630-639 (2012).
45. Schnitzler MA, Lentine KL, Axelrod D et al. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: Application to BENEFIT and BENEFIT-EXT trials. Transplantation 93(2), 172-181 (2012).
46. Durrbach A, Pestana JM, Pearson T et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10(3), 547-557 (2010).
47. Florman S, Bresnahan B, Chan L et al. Three year outcomes in Black/African American kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies. Am. J. Transplant. (Suppl. 2), Abstract 1091, 350 (2011).
48. Florman S, Becker T, Bresnahan B et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation BENEFIT & BENEFIT-EXT. Am. J. Transplant. 11 (Suppl. 2), Abstract 229, 100 (2011).
49. Rostaing L, Reyes-Acevedo R, Neumayer HH et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase 3 belatacept studies. Transplant. Int. 24(Suppl. s2), Abstract O-243 (2011).
50. Rostaing L, Massari P, Garcia VD et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized Phase II study. Clin. J. Am. Soc. Nephrol. 6(2), 430-439 (2011).
51. Grinyo J, Nainan G, del Rial M et al. Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: Results from the long-term extension of a Phase II study. Transplant. Int. 24(Suppl. s2), Abstract O-245, 70 (2011).
52. Ferguson R, Grinyó J, Vincenti F et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am. J. Transplant. 11(1), 66-76 (2011).
53. Haggerty HG, Proctor SJ. Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeys. Toxicol. Sci. 127(1), 159-168 (2012).
54. Grinyó J, Charpentier B, Pestana JM et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90(12), 1521-1527 (2010).
55. Vanrenterghem Y, Bresnahan B, Campistol J et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91(9), 976-983 (2011).
56. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88(4), 568-574 (2009).
57. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 86(3), 377-383 (2008).
58. Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 9(5), 1063-1071 (2009).
59. Larsen CP, Bray R, Gebel H, Ganguly B, Kulbokas EJ, Brickman D. Evaluation of donor-specific antibodies in kidney transplant patients treated with belataceptor cyclosporine-based immunosuppression in BENEFIT and BENEFIT-EXT. Transplant. Int. 24(Suppl. S2), Abstract O-244.).
60. Gill JS, Landsberg D, Johnston O et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 89(2), 178-184 (2010).
61. Zhang Q, Liang LW, Gjertson DW et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 79(5), 591-598 (2005). (Pubitemid 40365888)
62. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J. Am. Soc. Nephrol. 16(9), 2804-2812 (2005).
63. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am. J. Transplant. 12(3), 554-562 (2012).
64. Fine RN, Becker Y, De Geest S et al. Nonadherence consensus conference summary report. Am. J. Transplant. 9(1), 35-41 (2009).
65. Cibrik D, Steinberg S, West P et al. A phase 2 study to assess the safety and efficacy of alefacept (alef) in de novo kidney transplant recipients. Transplant. Int. 24(Suppl. s2), Abstract O-24770 (2011).
66. Vincenti F, Tedesco Silva H, Busque S et al. Efficacy and safety of CP-690,550-MPA combination regimens in de novo kidney transplant patients: 12-month final results of a phase 2b study. Am. J. Transplant. 11(30), Abstract 4 (2011).
67. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant. 6(5 Pt 1), 876-883 (2006). (Pubitemid 44356637)
68. Furuzawa-Carballeda J, Lima G, Alberú J et al. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4a senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. Clin. Exp. Immunol. 167(2), 330-337 (2012).